指南与共识前列腺癌

EAU-EANM-ESTRO-ESUR-SIOG前列腺癌指南小组关于局限性前列腺癌治愈性意图延迟治疗的共识声明

EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study).
指南 / 共识 · Eur Urol · 2019-10-03

该研究由EAU-EANM-ESTRO-ESUR-SIOG前列腺癌指南小组联合合作组织,通过三阶段方案(系统评价、两轮Delphi调查和共识会议)制定延迟积极治疗(DAT)所有领域的共识声明。共109名医疗从业者和16名患者完成两轮调查,129条声明中66条(51%)达成共识,共识会议对剩余声明投票后新增27条(43%)达成共识,总计93条(72%)声明达成共识。共识声明和发现有望指导和规范常规临床实践及研究,直至通过前瞻性比较研究和临床试验获得更高水平证据。

要点

  • 共93条(72%)声明达成共识,涵盖DAT的患者选择、随访监测、重新分类和结局指标。
  • 低危疾病活检病变范围的临床重要阈值及mpMRI在确定分期和侵袭性中的作用仍存在不确定性。
  • 共识声明旨在指导临床实践和研究,需前瞻性研究提供更高水平证据。

核心结论

  • 项目共达成93条(72%)共识声明,覆盖延迟积极治疗的全部领域。
  • 共识声明和发现有望指导和规范常规临床实践及研究,直至获得更高水平证据。

研究设计与样本

  • 方案驱动的三阶段研究:系统评价、两轮Delphi调查和共识小组会议。
  • 由EAU-EANM-ESTRO-ESUR-SIOG前列腺癌指南小组联合合作组织开展。
  • 109名医疗从业者和16名患者完成两轮调查;共识会议有32名医疗从业者和3名患者参加。

主要发现

  • 调查的129条声明中,66条(51%)在调查中达成共识。
  • 共识会议对剩余声明讨论投票后,新增27条(43%)达成共识。
  • 总体93条声明(72%)达成共识。
  • 低危疾病活检病变范围的临床重要阈值及mpMRI在确定分期和侵袭性中的作用仍存在不确定性。

临床怎么用

  • 共识声明可用于指导和规范局限性前列腺癌延迟积极治疗的常规临床实践。
  • 共识声明可为相关研究提供参考,直至前瞻性比较研究和临床试验提供更高水平证据。

局限性

  • 低危疾病活检病变范围的临床重要阈值尚不确定。
  • mpMRI在确定疾病分期和侵袭性作为纳入和排除标准的作用尚不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is uncertainty in deferred active treatment (DAT) programmes, regarding patient selection, follow-up and monitoring, reclassification, and which outcome measures should be prioritised. OBJECTIVE: To develop consensus statements for all domains of DAT. DESIGN, SETTING, AND PARTICIPANTS: A protocol-driven, three phase study was undertaken by the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Association of Urology Section of Urological Research (ESUR)-International Society of Geriatric Oncology (SIOG) Prostate Cancer Guideline Panel in conjunction with partner organisations, including the following: (1) a systematic review to describe heterogeneity across all domains; (2) a two-round Delphi survey involving a large, international panel of stakeholders, including healthcare practitioners (HCPs) and patients; and (3) a consensus group meeting attended by stakeholder group representatives. Robust methods regarding what constituted the consensus were strictly followed. RESULTS AND LIMITATIONS: A total of 109 HCPs and 16 patients completed both survey rounds. Of 129 statements in the survey, consensus was achieved in 66 (51%); the rest of the statements were discussed and voted on in the consensus meeting by 32 HCPs and three patients, where consensus was achieved in additional 27 statements (43%). Overall, 93 statements (72%) achieved consensus in the project. Some uncertainties remained regarding clinically important thresholds for disease extent on biopsy in low-risk disease, and the role of multiparametric magnetic resonance imaging in determining disease stage and aggressiveness as a criterion for inclusion and exclusion. CONCLUSIONS: Consensus statements and the findings are expected to guide and inform routine clinical practice and research, until higher levels of evidence emerge through prospective comparative studies and clinical trials. PATIENT SUMMARY: We undertook a project aimed at standardising the elements of practice in active surveillance programmes for early localised prostate cancer because currently there is great variation and uncertainty regarding how best to conduct them. The project involved large numbers of healthcare practitioners and patients using a survey and face-to-face meeting, in order to achieve agreement (ie, consensus) regarding best practice, which will provide guidance to clinicians and researchers.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Lam TBL, MacLennan S, Willemse PM, et al. EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). Eur Urol. 2019. PMID: 31587989. doi:10.1016/j.eururo.2019.09.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。